We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?
Read MoreHide Full Article
Key Takeaways
Moderna is expanding into RSV, seasonal flu and combination vaccines to reduce reliance on COVID-19 revenue.
mFlusiva is now available in the United States, while mCombriax is slated for a European launch in 2027.
Moderna faces competition from established vaccine makers as it pursues growth across respiratory markets.
Although Moderna (MRNA - Free Report) initially established itself as a leading COVID-19 vaccine maker, the company is focused on broadening its commercial portfolio to reduce its reliance on pandemic-era demand. Moderna’s expansion into other respiratory vaccine categories offers an avenue for growth, but competing against established players in these markets could prove challenging.
A Broader Respiratory Portfolio Creates New Growth Opportunities
Moderna’s respiratory business is gradually evolving beyond its COVID-19 vaccine franchise. It has expanded into RSV with mResvia and recently entered the seasonal influenza market with mFlusiva. The company has also expanded its portfolio to combination vaccines with mCombriax, which received EU approval in April 2026 as the first combination vaccine protecting against both influenza and COVID-19.
mFlusiva is now available in the United States for the 2026/2027 vaccination season, while Moderna is preparing to launch mCombriax in Europe next year. Management views Europe as a significant growth opportunity, particularly as a competitor’s COVID-19 vaccine contract is set to expire at the end of 2026. The company is also seeking broader international reach through long-term partnerships and regulatory expansion in markets outside the United States. Moderna is awaiting FDA guidance on refiling mCombriax, leaving another potential avenue to extend the combination-vaccine franchise.
However, COVID-19 vaccines are expected to remain the key driver of Moderna’s top-line revenues in the near term, given their established commercial base. The newer products offer opportunities to diversify revenues over time, but their contribution will depend on uptake and successful commercialization.
Moderna Faces Stiff Competition in Targeted Markets
Moderna continues to face stiff competition in the COVID-19 vaccine market, where it competes with Pfizer (PFE - Free Report) /BioNTech (BNTX - Free Report) and Sanofi/Novavax. As demand for COVID-19 vaccines has normalized, maintaining market share remains important to the company’s respiratory business. Competition could intensify further in the combination vaccines market as manufacturers develop products targeting both influenza and COVID-19, potentially increasing pressure on pricing and market share.
In RSV, Moderna’s mResvia competes with Pfizer’s Abrysvo and GSK’s (GSK - Free Report) Arexvy. The seasonal influenza market presents another challenge, with mFlusiva entering a market dominated by established players such as Sanofi, CSL Seqirus and GSK. Competition could become more intense as GSK advances its own mRNA-based flu vaccine following positive phase II results.
View the Zacks #1 Rank List
Image: Shutterstock
Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?
Key Takeaways
Although Moderna (MRNA - Free Report) initially established itself as a leading COVID-19 vaccine maker, the company is focused on broadening its commercial portfolio to reduce its reliance on pandemic-era demand. Moderna’s expansion into other respiratory vaccine categories offers an avenue for growth, but competing against established players in these markets could prove challenging.
A Broader Respiratory Portfolio Creates New Growth Opportunities
Moderna’s respiratory business is gradually evolving beyond its COVID-19 vaccine franchise. It has expanded into RSV with mResvia and recently entered the seasonal influenza market with mFlusiva. The company has also expanded its portfolio to combination vaccines with mCombriax, which received EU approval in April 2026 as the first combination vaccine protecting against both influenza and COVID-19.
mFlusiva is now available in the United States for the 2026/2027 vaccination season, while Moderna is preparing to launch mCombriax in Europe next year. Management views Europe as a significant growth opportunity, particularly as a competitor’s COVID-19 vaccine contract is set to expire at the end of 2026. The company is also seeking broader international reach through long-term partnerships and regulatory expansion in markets outside the United States. Moderna is awaiting FDA guidance on refiling mCombriax, leaving another potential avenue to extend the combination-vaccine franchise.
However, COVID-19 vaccines are expected to remain the key driver of Moderna’s top-line revenues in the near term, given their established commercial base. The newer products offer opportunities to diversify revenues over time, but their contribution will depend on uptake and successful commercialization.
Moderna is also making significant progress beyond vaccines. It recently made a breakthrough in oncology, reporting positive results from a phase III study evaluating its investigational mRNA-based cancer therapy developed in collaboration with Merck. The study met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in certain melanoma patients. Detailed results are expected later this month.
Moderna Faces Stiff Competition in Targeted Markets
Moderna continues to face stiff competition in the COVID-19 vaccine market, where it competes with Pfizer (PFE - Free Report) /BioNTech (BNTX - Free Report) and Sanofi/Novavax. As demand for COVID-19 vaccines has normalized, maintaining market share remains important to the company’s respiratory business. Competition could intensify further in the combination vaccines market as manufacturers develop products targeting both influenza and COVID-19, potentially increasing pressure on pricing and market share.
In RSV, Moderna’s mResvia competes with Pfizer’s Abrysvo and GSK’s (GSK - Free Report) Arexvy. The seasonal influenza market presents another challenge, with mFlusiva entering a market dominated by established players such as Sanofi, CSL Seqirus and GSK. Competition could become more intense as GSK advances its own mRNA-based flu vaccine following positive phase II results.